Molecular and Cell Biology of Human Gene Therapeutics
Seiten
1995
Chapman and Hall (Verlag)
978-0-412-62550-3 (ISBN)
Chapman and Hall (Verlag)
978-0-412-62550-3 (ISBN)
advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu lation. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation.
advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu lation. A differential response to immunotherapy is thus inevitable. 4. Many of the human trials described are not randomized and report survival or response against historical controls. Most tumors described are immunogenic human tumors: renal cell cancer and melanoma are most common. In order to avoid the well-described inter-patient vari ation and rare incidence of spontaneous response among patient samples as well as selection bias and changes in practice over time, randomized trials are required. 5. Immunological treatment is unlike conventional chemotherapy in its endpoint. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation. There are now many cases where immunotherapy has provided long-term palliation without massive tumor reduction. Immunity may be stimulated to a degree which holds tumorigenicity in check and most importantly, pro vides good palliation for the patient in a manner that differs essentially from chemotherapy.
advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu lation. A differential response to immunotherapy is thus inevitable. 4. Many of the human trials described are not randomized and report survival or response against historical controls. Most tumors described are immunogenic human tumors: renal cell cancer and melanoma are most common. In order to avoid the well-described inter-patient vari ation and rare incidence of spontaneous response among patient samples as well as selection bias and changes in practice over time, randomized trials are required. 5. Immunological treatment is unlike conventional chemotherapy in its endpoint. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation. There are now many cases where immunotherapy has provided long-term palliation without massive tumor reduction. Immunity may be stimulated to a degree which holds tumorigenicity in check and most importantly, pro vides good palliation for the patient in a manner that differs essentially from chemotherapy.
Retroviral vectors. Adenoviral vectors. Herpes simplex virus vectors. Liposome-mediated gene transfer. Intramuscular injection of plasmid DNA. Yeast artificial chromosome vectors. Gene transfer and cancer chemotherapy. Vaccine immunotherapy for cancer. Inherited immunodeficiencies. Anti-viral strategies. Aids and HIV infection. Cystic fibrosis and lung diseases. Arthritis. Duchenne muscular dystrophy. Cardiovascular disease. Degenerative and inherited neurological disorders. Mucopolysaccharidosis. DNA-based immunization. Index.
| Erscheint lt. Verlag | 31.5.1995 |
|---|---|
| Reihe/Serie | Molecular and Cell Biology of Human Diseases Series ; 20 |
| Zusatzinfo | XV, 403 p. |
| Verlagsort | London |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| ISBN-10 | 0-412-62550-4 / 0412625504 |
| ISBN-13 | 978-0-412-62550-3 / 9780412625503 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller
Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
CHF 30,75
Die revolutionäre Medizin von morgen (Lifespan)
Buch | Softcover (2020)
DuMont Buchverlag
CHF 22,40
Buch | Softcover (2022)
John Wiley & Sons Inc (Verlag)
CHF 169,95
